key: cord-0899425-cfdnpscx
authors: Meshram, Hari Shankar; Kute, Vivek B.; Shah, Nauka; Chauhan, Sanshriti; Navadiya, Vijay V.; Patel, Ansy H.; Patel, Himanshu V.; Engineer, Divyesh; Banerjee, Subho; Rizvi, Jamal; Mishra, Vineet V.
title: COVID-19 in Kidney Transplant Recipients Vaccinated With Oxford–AstraZeneca COVID-19 Vaccine (Covishield): A Single-center Experience From India
date: 2021-05-26
journal: Transplantation
DOI: 10.1097/tp.0000000000003835
sha: db73582296307b181aa8f14142039ae6c001096a
doc_id: 899425
cord_uid: cfdnpscx

[Image: see text]

S evere acute respiratory syndrome coronavirus (SARS-CoV2) has been reporting global peaks in India in April 2021. The enormous task of vaccinating such a bulk population has become more difficult in the state where health resources for managing coronavirus disease 2019 (COVID-19) are rapidly emptying amid the COVID-19 surge. Indian advisories have approved 2 vaccines: Oxford-AstraZeneca COVID-19 (Covishield) and BBV152 (Covaxin) as of April 2021. The efficacy of these vaccines has been reported lesser compared with the mRNA vaccines in general population. 1,2 Preliminary reports with mRNA vaccine in organ transplant patients have shown that around 75% of transplant patients have a suboptimal response to mRNA COVID-19 vaccine. 3 Such data with Covishield vaccine are lacking. We report 4 cases of COVID-19 in kidney transplant recipients (KTRs) 2 of them after 2 doses of Covishield vaccine and another 2 after a single dose. The study is approved by the Institutional Ethics committee. We also abided by the Declaration of Helsinki and Declaration of Istanbul principles. None of them reported any minor or major side effects postvaccination. The probable exposure was community acquired in all the 4 cases. Three patients were on triple immunosuppression. Three cases required critical care admission and received steroids, remdesivir, anticoagulation, and investigational therapies (patient 1: tofacitinib and bevacizumab; patient 2: COVID-19 convalescent plasma) as anti-COVID-19 therapy during the stay. Patient 1 died and patients 2 and 3 are on mechanical ventilation with a poor prognosis (Table 1) . Patient 4 had a mild COVID-19 course being managed at home. Time from the second dose of vaccine to onset of symptoms was 20 and 8 d for patients 1 and 4, respectively. Patients 2 and 3 developed symptoms after 13 and 23 d of the first dose of vaccine, respectively. SARS-CoV2 IgG antibody response was suboptimal in 3 cases, while seroconversion developed in patient 1. To the best of our knowledge, this is the first report of COVID-19 postvaccination after Covishield vaccine in KTRs. The documentation of attenuated response in our report bolsters our speculation that antibody response after Covishield might be suboptimal in KTRs. The recent reports 3 of insufficient antibody response from mRNA vaccine whose efficacy is around 95% in general population compared with the lower efficacy vaccine used in Indian settings is alarming for the immunosuppressed group as they will have further attenuated response. The outcome of vaccinated patients acquiring COVID-19 is sparsely reported. There have been a few reports of COVID-19 infection postvaccination in organ transplants after mRNA vaccines. 4, 5 In conclusion, critical COVID-19 despite vaccination in our report is concerning and it emphasizes the fact that KTRs are more prone to COVID-19 even after vaccination. Hence, safety measures to prevent disease transmission should be continued. There is a special need to find a definitive therapy for COVID-19, as reports of vaccine efficacy in transplants are worrisome. The future implications of our report highlight the need for further research with reporting of outcome of vaccinated patients, efficacy of different vaccines, dosages, e101 

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients

COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination

The authors declare no funding or conflicts of interest. Data will be available from the corresponding author on request.All authors contributed equally to the conception and design of the work; acquisition, analysis, interpretation of data; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work.

The authors express our sincere gratitude to all the resident doctors and healthcare staffs who are tirelessly doing a mammoth job of managing the COVID-19 cases in India, despite facing resource crisis.